Prescription Drug Price Transparency
Related Sites
Prescription Drug Price Transparency
Public Interest Drug Lists
The Minnesota Legislature expanded the Minnesota Prescription Drug Price Transparency Act in 2023 to include reporting from drug manufacturers, pharmacy benefit managers, wholesalers, and pharmacies on drugs of substantial public interest. The Minnesota Department of Health (MDH) is responsible for producing and publicly posting quarterly lists of the prescription drugs requiring reporting.
On April 23, 2024, MDH released draft methodology for the inaugural list of drugs of substantial public interest to invite public feedback. After considering comments, MDH produced and posted the inaugural list on June 26, 2024. Manufacturers, pharmacies, wholesalers, and PBMs with a reporting obligation will be notified of the requirement to report no sooner than 30 days after this release; they will have 60 days after the date of notification to report data to MDH.
Existing lists
- List of Drugs of Substantial Public Interest—June 2024 (Excel) and List Methodology for Drugs of Substantial Public Interest Reporting (PDF)
- Previous lists: N/A
Future lists
MDH will continue to seek public input for future lists using various strategies. MDH expects to adjust the release of subsequent lists to ensure no more than one list is released quarterly. Reporting entities will have approximately 90 days to report after each list is released (notifications will be sent 30 or more days after the list is released; reports are due 60 days after notifications are sent).
The Minnesota Department of Health (MDH) wants to hear from you!
Have prescription drug prices impacted your health care? What do you think is creating affordability challenges for patients? What drugs – and their prices – have a substantial public interest and would benefit from pricing transparency?
By completing the Public Input on Prescription Drug Price Transparency in Minnesota form, you can: share your experiences and suggest where you think MDH should focus its drug price transparency work.